Bruce Berkowitz Fairholme Capital Management
Bruce Berkowitz is the founder of Fairholme Capital Management and a concentrated value investor known for bold, high-conviction portfolios. He rose to prominence managing mutual fund assets with a willingness to take large positions in out-of-favor financials and special situations. Berkowitz’s approach prioritizes intrinsic value estimates and a short list of ideas rather than broad diversification.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$18M |
| 2 |
Berkshire Hathaway Class A
BRK.A
|
+$6.49M |
| 3 |
Pfizer
PFE
|
+$6.04M |
| 4 |
United Parcel Service
UPS
|
+$2.47M |
| 5 |
Campbell Soup
CPB
|
+$2.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
St. Joe Company
JOE
|
+$67.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 76.43% |
| 2 | Energy | 13.46% |
| 3 | Financials | 9.02% |
| 4 | Consumer Staples | 0.49% |
| 5 | Healthcare | 0.37% |
Similar funds
Bruce Berkowitz's Q2 2026 Portfolio in Review
As of Q2 2026, Bruce Berkowitz held 13 positions worth $1.49B, down 1.6% from $1.51B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Bruce Berkowitz's Q2 2026 filing shows 3 new, 4 increased and 1 reduced positions. Its largest new stake was Pfizer: 231,000 shares worth $5.56M. The largest sale was St. Joe Company, an estimated $67.4M.
By sector, the portfolio is most concentrated in Real Estate at 76% of assets, down from 80% a quarter earlier, followed by Energy and Financials.
- Bruce Berkowitz's largest Q2 2026 buy was Pfizer: 231,000 shares worth $5.56M.
- Bruce Berkowitz added most to Berkshire Hathaway Class B in Q2 2026, an estimated $18M increase.
- Bruce Berkowitz's biggest Q2 2026 reduction was St. Joe Company, cutting an estimated $67.4M.
- Bruce Berkowitz's ten largest holdings make up 100% of its $1.49B portfolio in Q2 2026.
- Bruce Berkowitz opened 3 new positions and closed 0 in Q2 2026.
- Bruce Berkowitz's portfolio value fell 1.6% quarter-over-quarter to $1.49B.
Based on Fairholme Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.